Estrogen as treatment of hemorrhagic cystitis in children and adolescents undergoing bone marrow transplantation.
Hemorrhagic cystitis (HC) after allogeneic hematopoietic stem cell transplantation (HSCT) can cause significant morbidity and mortality. Previous reports have suggested a role for estrogen in the control of HC in adult patients. Here, we describe the clinical courses of 10 children and adolescents treated with estrogen for HC following HSCT. Eight patients (80%) experienced a significant improvement in their hematuria following the commencement of therapy, with six (60%) undergoing resolution of macroscopic hematuria, without any recurrences. The treatment was well tolerated by the majority of patients, with only one patient needing to interrupt treatment (hepatotoxicity). We conclude that estrogen is well tolerated and often effective, and should be considered as an adjunctive treatment option in children and adolescents with HC following HSCT.
Heath
J A
JA
Children's Cancer Centre, Royal Children's Hospital, Parkville, Australia. john.heath@rch.org.au
Mishra
S
S
Mitchell
S
S
Waters
K D
KD
Tiedemann
K
K
D000293:Adolescent; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000379:methods; D056486:Chemical and Drug Induced Liver Injury; D002648:Child; D003556:Cystitis / Q000188:drug therapy* / Q000473:pathology; D004967:Estrogens / Q000008:administration & dosage* / Q000633:toxicity; D005260:Female; D006417:Hematuria / Q000188:drug therapy; D006470:Hemorrhage; D006801:Humans; D008297:Male; D016896:Treatment Outcome
D004967:Estrogens